Efficacy, Safety, and Tolerability of Oral Eletriptan for Treatment of Acute Migraine
Status:
Completed
Trial end date:
1997-12-01
Target enrollment:
Participant gender:
Summary
To confirm the efficacy of three dose levels of oral eletriptan relative to placebo in
relieving symptoms of acute migraine and to further explore the dose response relationship of
eletriptan.
Phase:
Phase 3
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.